Newly released study results demonstrate that Yescarta, a CAR T therapy, prolongs survival longer than standard care for patients with early relapsed or refractory DLBCL
Cancer Treatment CAR T Therapy Prolongs Survival Over Standard Care
Newly released study results demonstrate that Yescarta, a CAR T therapy, prolongs survival longer than standard care for patients with early relapsed or refractory DLBCL